<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015041521787N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2015-09-14</date_registration>
      <primary_sponsor>Vice chancellor for research, Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The role of antibiotics in mandibular fractures</public_title>
      <acronym></acronym>
      <scientific_title>The role of postoperative antibiotics in prevention of infection at open reduction of mandibular compound fractures</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-09-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/18992</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Mandibular fracture.</hc_freetext>
      <i_freetext>Intervention 1: Patients diagnosed with open fractures of the mandible were placed on two groups: Antibiotic group or non antibiotic group and they receive 2-5 day  preoperatively 1gr Cefazolin IV qid. Antibiotics 1gr Cefazolin IV were continued for 30 minutes before surgery. At the time of the surgery all the patients received intraoperative antibiotics which consisted of Cefazolin IV 1gr (900 mg clindamycin IV if allergic to penicillin). At the conclusion if the procedure is going to take more than 5 hours the patients would receive 1gr Cefazolin IV. At the end of the surgery the patients were randomized into 2 groups ( antibiotic group and non antibiotic group). The antibiotic group receive 600mg Clindamycin IV tds 7 days postoperative with chlorhexidine gluconate 0.12% oral rinse. The drug company is Dana Tabriz, Iran. Intervention 2: Patients diagnosed with open fractures of the mandible were placed on two groups: Antibiotic group or non antibiotic group and they  receive 2-5 day  preoperatively 1gr Cefazolin IV qid. Antibiotics 1gr Cefazolin IV were continued for 30 minutes before surgery. At the time of the surgery all the patients received intraoperative antibiotics which consisted of Cefazolin IV 1gr (900 mg clindamycin IV if allergic to penicillin). At the conclusion if the procedure is going to take more than 5 hours the patients would receive 1gr Cefazolin IV. At the end of the surgery the patients were randomized into 2 groups ( antibiotic group and non antibiotic group). The non Ab group receive placebo drug for 7 days with chlorhexidine gluconate 0.12% oral rinse.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mehrnoush Momeni Rouchi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dental School of Tehran university of medical science, Hakim street, Kargar street, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8835 1150</telephone>
        <email>m-nobari@student.tums.ac.ir ; minnobari@yahoo.com</email>
        <affiliation>Tehran university of medical science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mehrnoush Momeni Rouchi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran university of medical science, Hakim street, Kargar street, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8835 1150</telephone>
        <email>m-nobari@student.tums.ac.ir ; minnobari@yahoo.com</email>
        <affiliation>Tehran university of medical science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Open reduction and internal fixation; At least 1 fracture of mandible; Follow up of at least 5 weeks.&#13;
Exclusion criteria: Infection during surgry; Gunshot wounds; Need for intensive care; Presence of an acute bacterial infection; Pathological fractures; Fracture of the skull base; History of malignancy/ radiation of the head and neck area; Immunosuppression; Reduced body weight; Kidney disease; Inter Maxillary Fixation; Insufficient follow up</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S02.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lower jaw (bone)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Patients diagnosed with open fractures of the mandible were placed on two groups: Antibiotic group or non antibiotic group and they receive 2-5 day  preoperatively 1gr Cefazolin IV qid. Antibiotics 1gr Cefazolin IV were continued for 30 minutes before surgery. At the time of the surgery all the patients received intraoperative antibiotics which consisted of Cefazolin IV 1gr (900 mg clindamycin IV if allergic to penicillin). At the conclusion if the procedure is going to take more than 5 hours the patients would receive 1gr Cefazolin IV. At the end of the surgery the patients were randomized into 2 groups ( antibiotic group and non antibiotic group). The antibiotic group receive 600mg Clindamycin IV tds 7 days postoperative with chlorhexidine gluconate 0.12% oral rinse. The drug company is Dana Tabriz, Iran.</i_keyword>
      <i_keyword>Patients diagnosed with open fractures of the mandible were placed on two groups: Antibiotic group or non antibiotic group and they  receive 2-5 day  preoperatively 1gr Cefazolin IV qid. Antibiotics 1gr Cefazolin IV were continued for 30 minutes before surgery. At the time of the surgery all the patients received intraoperative antibiotics which consisted of Cefazolin IV 1gr (900 mg clindamycin IV if allergic to penicillin). At the conclusion if the procedure is going to take more than 5 hours the patients would receive 1gr Cefazolin IV. At the end of the surgery the patients were randomized into 2 groups ( antibiotic group and non antibiotic group). The non Ab group receive placebo drug for 7 days with chlorhexidine gluconate 0.12% oral rinse.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Infection. Timepoint: Follow up appointments were 1,3,5 weeks postoperatively. Method of measurement: Infection, Inflammation, Erythema, Fever, Drainage.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-06-16</approval_date>
        <contact_name>Ethics committee of Tehran university of medical science</contact_name>
        <contact_address>Ghods central building, Ghods street, Keshavarz street, Tehran, Iran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
